Through these mechanisms, CTGF exhibits a pro-fibrotic effect, with increased concentration of CTGF observed in the BAL fluid of pulmonary fibrosis patients [421,422], while therapy with pamrevlumab led to a significant improvement in lung function dynamics [423]. The gene discussed is CCN2; the disease is pulmonary fibrosis.